OVER THE LAST YEAR, companies like GlaxoSmithKline, Bristol-Myers Squibb, Och-Ziff, and AB InBev joined an illustrious list that includes Siemens, Kellogg Brown Root, Technip, and Eni.
What do they all have in common?
Each has now paid significant fines – and in at least one case, seen jail time for their CEO – related to violations of the U.S. Foreign Corrupt Practices Act that involve joint ventures in emerging markets.
